Hemopericardium with tamponade following rivaroxaban administration and its attenuation by CYP3A4 inhibitors.
Novel oral anticoagulants including the factor Xa inhibitor rivaroxaban are important alternatives to warfarin for the prevention of thromboembolic stroke in patients with nonvalvular atrial fibrillation. The pharmacology and metabolism of these agents differ from those of the vitamin K antagonists used over the decades preceding their introduction. We present a case of spontaneous hemopericardium and cardiac tamponade following administration of rivaroxaban. A review of the patient's medications revealed a total of seven agents known to be metabolized through cytochrome P450 3A4 (CYP3A4), the major pathway for rivaroxaban metabolism. While most physicians are familiar with recommendations to monitor renal function in patients prescribed rivaroxaban, we suspect that many fail to evaluate possible interactions with other agents having CYP3A4 inhibitory or inducer activity.
Division of Cardiology, Baylor Scott & White Health Memorial Hospital, Temple, Texas (Menendez, Michel); and Texas A&M University Health Science Center College of Medicine, Temple, Texas.
Denisse
D
Menendez
Division of Cardiology, Baylor Scott & White Health Memorial Hospital, Temple, Texas (Menendez, Michel); and Texas A&M University Health Science Center College of Medicine, Temple, Texas.
Jeffrey
J
Michel
Arrhythm Electrophysiol Rev. 2013 Nov;2(2):115-9
26835051
Pharmacotherapy. 2014 Sep;34(9):e169-72
25074401
Br J Clin Pharmacol. 2016 Apr;81(4):724-34
26580706
Br J Clin Pharmacol. 2013 Sep;76(3):455-66
23305158
Br J Clin Pharmacol. 2010 Nov;70(5):703-12
21039764
Biomed Chromatogr. 2016 Oct;30(10 ):1556-72
27006091